Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of salicylic acid and escitalopram (abbreviated as ESP). Salicylic acid is a keratolytic agent commonly used topically to treat skin conditions such as acne, psoriasis, warts, and calluses. It works by promoting the shedding of the outer layer of skin and has anti-inflammatory properties. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) primarily used for the treatment of depression and anxiety disorders; it increases serotonin levels in the brain by inhibiting its reuptake into presynaptic cells. There are experimental approaches where ion-pairing strategies combine organic acids like salicylic acid with escitalopram to enhance transdermal delivery of the SSRI[4]. However, this combination does not appear to be an approved or marketed pharmaceutical product but rather an experimental formulation for research on transdermal drug delivery systems[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salicylic acid + escitalopram.